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Abstract: 
  In the current study hundred ten of Iraqi patients with colorectal tumors were studied to evaluate the expression 
of wild BRAF and BRAFV600E using Tissue microarray-Immunohistochemisty (TMA-IHC) technique. Of them, 
Ninety cases had colorectal carcinoma, and twenty had benign tumors. A group of twenty cases of non-specific 
colitis and other twenty colonic biopsies with no significant pathology were also studied. Results of the study 
demonstrated that BRAF expression was positive in 86.7% of carcinoma cases, and there was significant 
differences (P=0.038) in the expression of BRAF within tumor stages. Whereas BRAFV600E expression was 
negative in groups of adenoma, colitis and cases with no significant pathology compared to carcinoma group in 
which 13.3% showed positive expression. We found significant correlation between the expression of 
BRAFV600E and the age (P=0.047), right sided colon tumor (P=0.041), and mucinous type carcinoma (P=0.021). 
And there was significant differences between wild BRAF and mutant BRAFV600E in age, female gender, right-
sided colon tumor, tumor grade, and type of tumor (p=0.0001). 
Keywords: BRAF, mutant BRAF, CRC,  prognostic markers in CRC. 
 
1. Introduction: 
 Among the various types of cancers, colorectal cancer (CRC) is a serious and common health problem 
worldwide. This cancer is the third most common visceral malignancy with nearly 1.4 million new cases 
diagnosed in 2012[1].  Despite advances in surgical techniques and therapeutic interventions during the past few 
decades, CRC remains a major health problem worldwide due to therapy resistance [2, 3].  Studies aiming at 
optimizing the diagnostic process and treatment of this disease are increasing, which has probably caused CRC to 
be one of the most-studied and best characterized processes of tumorigenesis. Through more biological 
knowledge of tumorigenesis in CRC, more emphasis on early detection and development of new and improved 
treatment regimens [4, 5]. Because CRC is a major cause of cancer related deaths worldwide, a lot of researches 
have been focused on the discovery and development of biomarkers to improve the diagnostic process and to 
predict treatment outcomes. Up till now only a few biomarkers are recommended by expert panels. Discovery of 
additional prognostic markers might permit the development of guidelines for better management of CRC in 
order to improve overall survival [6]. Of them, the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF), a 
member of the RAF family of serine/threonine protein kinases that displays the best binding to RAS and has the 
highest phosphorylating activity [7]. Active RAS induces conformational changes in RAF that allows its 
recruitment to the cell membrane, promoting changes in the phosphorylation status and triggering its kinase 
activity [8]. Different genetic aberrations of BRAF have been reported in various malignancies [9, 10].  Mutations 
in BRAF and RAS generally occur in a mutually exclusive fashion, suggesting that aberrant regulation of the 
RAS/ BRAF/MEK/ERK pathway may be the pathogenesis of these tumor types, which can be achieved at 
different levels of the pathway [11].  The predominant mutation in the BRAF gene involves a thymidine to 
adenosine transversion at nucleotide 1799(T1799A), accounting for greater than 90% of the observed mutations 
in BRAF [12]. BRAF gene mutation testing has emerged as an important tool for diagnosis, prognosis, treatment, 
and predicting patient outcome in response to targeted therapy for multiple cancer types. V600E is the most 
common  mutation for the BRAF [13]. Until recently, the detection of BRAF mutations was performed with 
Sanger sequencing or PCR-based assays. These methods require representative amount of malignant cells and 
extraction of the DNA. Immunohistochemical detection of BRAF with a mutation specific antibody was first 
described in metastatic melanoma and papillary thyroid carcinoma [14]. The advantage of  
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immunohistochemistry (IHC) lies in the minimal amount of the needed tissue and the availability of this 
technique in most pathological laboratories [15, 16]. 
 
2. Materials & Methods: 
 A total of 150 cases of colonic biopsies were collected. Among these, 90 cases colorectal cancer, 20 cases 
benign lesions, 20 cases non-specific colitis and 20 cases reveal no significant pathology.   Clinical information 
regarding patient's age, tumor size, grade, and pathological stage was obtained from the available histological 
reports. Hematoxylin and Eosin (H&E) stained sections were re-examined by two pathologists. All the 
preparations for tissue microarray (TMA) and immunohistochemistry (IHC) were performed in Pathology Unit - 
Southern General Hospital (SGH), University of Glasgow, United Kingdom.   
  2.1 Construction of tissue microarrays (TMAs) 
  Tissue cores of 0.6 mm in size were obtained from three paraffin-blocks in this cohort. Five tumor tissue cores 
(0.6mm in diameter) were taken from each paraffin block with Beecher automated tissue arrayer (Beecher 
Instruments, Sun Prairie, Wisconsin, USA). The cores were placed in a new recipient paraffin block that 
ultimately contained 325 tissue cores. The information of all TMAs cases were put in data sheet which called 
TMA map. This TMA map consists of a simple excel sheet, which served as a guideline to blocks arrangement 
and sequence in which they arrayed. Thus the TMA map was contained the exact location for each core in TMAs 
slide or block and another map (TMA code map) contained the code number for each core to each block. TMA 
block was cut at a thickness of 5µm on a microtome cutter (Leica RM2235). Sections were then placed on 
Salinized coated slides, (DAKO, UK) and heated at 58°C for 24 hours. 
  2.2  TMA- Immunohistochemistry:   
  IHC was applied on TMA sections. Staining was carried out for wild and mutant BRAF.  Sections were 
deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol (100%, 90%, 80%, 70%). 
Antigen was retrieved using citrate buffer (prepared by dissolving 2.1 gm of citric acid powder into 1 litre of 
dH2O, adjust pH to 6) for 10 min in pressure cooker. Slides were incubated in peroxidase – blocking solution 
(Dako, ready- to- use) for 20 minutes. Non-specific binding of antibodies was blocked by the addition of 2.5% 
normal horse serum, from (ImmPRESS™  ,Vector , USA). 
 Primary antibodies were diluted (1:100 ) for wild BRAF and (1:50) for BRAFV600E using antibody diluant (ready-
to-use, Code no. ADS-125, Spring Bioscience,USA), and incubated overnight at 4°C. Rat monoclonal antibodies 
kit (Spring Bioscience, USA) was used to detect primary antibodies for wild BRAF. Whereas mouse monoclonal 
antibodies kit (Spring Bioscience, USA) was used to detect primary antibodies for BRAFV600E.  Secondary 
antibodies for wild BRAF (Anti Rat  Ig.  peroxidase , Cat. No. MP-7404, ImmPRESS™ Vector, USA), and for 
BRAFV600E (Anti mouse Ig. peroxidase , Cat. No. MP-7402, ImmPRESS™  Vector, USA)  were  applied to the 
slides and incubated for 30 minutes at room temperature in a humidified chamber. The colorimetric detection of 
reaction was achieved by the Diaminobenzidine (DAB) Peroxidase Substrate method. Then, sections were 
counterstained with haematoxylin, dehydrated, and mounted. Tissue microarray slides scanned by using of digital 
image scanning analysis computer,( NDP, U10074-01, UK). 
 2.3 Scoring system of IHC in TMAs: 
For BRAF and BRAF V600E, the positive expression was observed as a diffuse brown cytoplasmic staining. Any 
cytoplasmic staining was recorded as positive expression, irrespective to the intensity of staining according to 
Nicolas et al. 2015. The score was done taking into account the percentage of positively staining tumor cells with 
no relation to signal intensity: tumors were assessed as BRAF negative if >90% of the cancer cells were 
unstained (<10% of positive cells) and as BRAF positive if more than 10% of cells were immune stained [17]. 
Statistical analyses 
Statistical analysis was carried out using (SPSS V. 20). The association between wild and mutant BRAF, 
and patients' clinico-pathological features was assessed by chi -square test and Fisher exact test when the 
Chi square test  was not  fi t .  Statistical tests were approved by assuming a null hypothesis of no difference 
between variables, a probability was considered statistically significant when P values ≤ 0.05. 
 
3. Results & Discussion: 
       3.1 TMA Immunohistochemical expression of BRAF: 
    In current study, wild BRAF was positive in 70% of colonic adenoma, and in 86.7% of colorectal carcinoma 
(Figures 1 & 2). 
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Figure (1) Expression of BRAF in Colonic Adenoma and Colorectal Carcinoma. 
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Figure(2)Immunohistochemical Assessment Of BRAF A: Villous Adenoma Showing Positive Expression Of 
BRAF(Hematoxylin & DAB(20X) , B: Tubular Adenoma  Showing Positive Cytoplasmic Expression Of BRAF, 
(Hematoxylin & DAB(30X)  C:Tubulovillous Adenoma Showing Positive Cytoplasmic Expression Of BRAF, 
(Hematoxylin & DAB(30X) D: Moderatelly Differentiated Adenocarcinoma Showing Diffuse Cytoplasmic 
Positive Expression Of BRAF(Hematoxylin & DAB(20X) E: Well Differentiated Adenocarcinoma Showing 
Diffuse Cytoplasmic Positive Expression Of BRAF(Hematoxylin & DAB(20X)  F: Well Differentiated 
Adenocarcinoma Showing Negative Expression Of BRAF, (Hematoxylin & DAB(30X) 
 
In colitis group, 25% of cases were positive BRAF expression (Figure 3 &5) whereas 40% of positive cases were 
distinguished in cases without significant pathology (Figure 4 & 5).  
 
 
Figure (3) Expression of BRAF within Colitis Group. 
 
 
Figure (4) Expression of BRAF within Cases of No Significant Pathology  
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Figure(5)Immunohistochemical Assessment Of BRAF ( A: Non Specific Colitis Tissue Showing Positive 
Expression Of BRAF(Hematoxylin & DAB(20X) , B: Normal Colon Tissue Showing Positive Cytoplasmic 
Expression Of BRAF, (Hematoxylin & DAB(30X)   
3.2Association of BRAF expression with clinicopathological features: 
3.2.1 Association of BRAF expression with age: 
Results revealed that there were no significant differences in BRAF expression within age groups (Table1). 
Table (1) Association of BRAF Expression with Age 
Groups Age 
(years) 
No. of cases 
n          % 
Negative 
n          % 
Positive 
n          % 
Fisher exact 
test 
*P 
value 
Carcinoma ≤ 55 43        47.7 5            5.5 38            42.2 0.2 0.527 
> 55 47        52.3 7            7.8 40             44.5 
Adenoma ≤ 55 14            70 4            20 10              50 0.4 1.00 
> 55 6            30 2            10 4                20 
Colitis ≤ 55 16             80 11            55 5                 25 0.3 0.530 
> 55 4               20 4             20 0             0 
No 
significant 
pathology 
≤ 55 17             85 9               45 8               40 0.2 0.242 
> 55 3               15 3               15 0                0 
 (*P˂ 0.05) 
3.2.2 Association of BRAF expression with gender: 
Results found out that no significant differences in BRAF expression between males and females in malignant 
cases, but there was a significant difference (P=0.032) in the expression of this marker between males and 
females in adenoma cases, only (2\18)of males showed positive BRAF expression, in contrast, all females 
showed positive expression of this marker (Table 2). 
 
Table (2) Association of BRAF Expression with Gender 
Groups Gender No. of cases 
n          % 
Positive 
n          % 
Negative 
n          % 
Fisher exact 
test 
*P 
value 
Carcinoma Male 53          58.8 43         47.7 10          11.1 7.1 0.116 
Female 37         41.2 35           39 2              2.2 
Adenoma Male 18          90 2          10 16           80 3.2 0.032 * 
Female 2          10 2          10 ---          --- 
Colitis Male 12          60 ---          --- 12            60 1.0 0.147 
Female 8          40 2         10 6             30 
No 
significant 
pathology 
Male 14          70 5         25 9             45 0.3 0.642 
Female 6          30 3          15 3             15 
 (*P˂ 0.05) 
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3.2.3Association of BRAF expression with tumor site: 
This study showed no significant differences in BRAF expression and tumor location in adenoma and carcinoma 
groups (Table 3). 
 
Table (3) Association of BRAF Expression with Tumor Site. 
Groups Tumor location No. of cases 
n          % 
Positive 
n          % 
Negative 
n          % 
Fisher 
exact test 
*P 
value 
Carcinoma Rt.Colon 28         31 23         25.5 5          5.5 0.1 0.307 
Lt.Colon 62         69 55          61.1 7          7.8 
Adenoma Rt.Colon 4          20 4             20 ---          --- 0.2 0.267 
Lt.Colon 16          80 10          50 6         30 
  (*P˂ 0.05)  
3.2.4Association of BRAF expression with tumor type, grade & stage: 
  Results showed that there were significant differences (P=0.038) in the expression of BRAF within tumor 
stages, the largest proportion of positive expression of BRAF was in cases within stage C (C1=15.5%, 
C2=22.2%), but there were no significant correlations between the expression of this marker and tumor type or 
grade (Table 4). 
Table (4) Association of BRAF Expression with Tumor Type, Stage and Grade. 
Carcinoma group No. of cases 
n          % 
Positive 
n          % 
Negative 
n          % 
Fisher exact 
test 
*P 
value 
Histological 
type 
Adenocarcinoma 81          90 72        80 9          10 6.5 0.077 
Mucinous 9         10 6            6.7 3          3.3 
Histological 
grade 
Well diff. 29          32.3 26          28.9 3          3.3 2.4 0.283 
Moderately diff. 25          27.7 23          25.5 2         2.2 
Poorly diff. 36          40 29          32.3 7          7.8 
Dukes stage A 15         16.7 14          15.5 1            1.1 2.0 0.038 * 
B 1 15          16.7 14          15.5 1            1.1 
B 2 19          21.1 16          17.8 3            3.3 
C 1 21          23.3 14          15.5 7 7.8 
C 2 20          22.2 20          22.2 0 0 
(*P˂ 0.05) 
3.3 TMA Immunohistochemical expression of BRAFV600E: 
BRAFV600Ewas scored the same way of BRAF, taking into account the percentage of positive staining  cells, 
regardless to the intensity of staining [17]. Results of BRAFV600E expression in groups of adenoma, colitis and 
cases with no significant pathology, showed negative expressions when stained with this marker in comparison 
to carcinoma group in which 13.3% were positive expression (Figures 6 & 7). 
 
 
Figure (6) Expression of BRAFV600E in Colonic Adenoma and Colorectal Carcinoma 
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Figure (7) Immunohistochemical Assessment Of BRAFV600E  A: Well  Differentiated Adenocarcinoma Showing 
Negative Expression Of BRAFV600E , ( Hematoxylin & DAB, 20X)  B: Well  Differentiated Adenocarcinoma 
Showing Positive Cytoplasmic Expression Of BRAFV600E,(Hematoxylin & DAB, 30X) C: Poorly Differentiated 
Adenocarcinoma Showing Positive Expression Of BRAFV600E, (Hematoxylin & DAB, 20X)  D: Normal Colon 
Tissue Showing Negative Expression Of BRAFV600E, (Hematoxylin & DAB, 20X). 
 
3.4 Association of BRAFV600Eexpression with clinicopathological features: 
3.4.1 Association of BRAFV600E expression with age: 
Results showed significant correlation (P=0.047) between the expression of BRAFV600E and the age in carcinoma 
group, that is, all BRAFV600E positive expression was detected in age group >55(Table 5). 
 
Table (5) Association of  BRAFV600E Expression with Age. 
Groups Age 
(years) 
No. of cases 
n          % 
Negative 
n          % 
Positive 
n          % 
Fisher exact 
test 
*P 
value 
Carcinoma ≤ 55 43          47.7 43          47.7 0           0 2.6 0.047 * 
> 55 47          52.3 35            38.9 12          13.3 
Adenoma ≤ 55 14            70 14            70 0              0 1.00 1.00 
> 55 6            30 6             30 0              0 
Colitis ≤ 55 16           80 16           80 0              0 1.00 1.00 
> 55 4            20 4            20 0              0 
No 
significant 
pathology 
≤ 55 17          85 17              85 0             0 1.00 1.00 
> 55 3           15 3               15 0             0 
(*P˂ 0.05) 
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3.4.2Association of BRAFV600E expression with gender: 
No significant differences were found in the expression of BRAFV600E between male and female in the all studied 
groups (Table 6). 
Table (6) Association between the expression of BRAFV600E and gender. 
Groups Gender No. of cases 
n          % 
Positive 
n          % 
Negative 
n          % 
Fisher exact 
test 
*P 
value 
Carcinoma Male 53          58.8 5           5.6 48          53.3 0.2 0.638 
Female 37         41.2 7          7.7 30         33.3 
adenoma Male 18           90 ---          --- 18          90 1.0 1.00 
Female 2           10 ---          --- 2          10 
Colitis Male 12           60 ---          --- 12          60 1.0 1.00 
Female 8           40 ---          --- 8          40 
No 
significant 
pathology 
Male 14           70 ---          --- 14          70 1.0 1.00 
Female 6          30 ---          --- 6          30 
  (*P˂ 0.05)   
3.4.3 Association of BRAFV600E expression with tumor site: 
    A significant differences (p=0.041) were found in the expression of BRAFV600E between right and left colon, 
since the positive expression was more in right colon tumors. (Table7). 
Table (7) Association between the Expression of BRAFV600E and Tumor Site. 
Groups Tumor site No. of cases 
n          % 
Positive 
n          % 
Negative 
n          % 
Fisher exact 
test 
*P 
value 
Carcinoma Rt.Colon 28         31.1 8           8.9 20          22.2 3.2 0.041* 
Lt.Colon 62         68.9 4           4.4 58          64.5 
Adenoma Rt.Colon 4           20 ---          --- 4            20 1.0 1.00 
Lt.Colon 16          80 ---          --- 16           80 
  (*P˂ 0.05)  
3.4.4 Association of BRAFV600E expression with tumor type, stage & grade: 
   Results showed no significant differences in the expression of BRAFV600E with stages and grades of the tumor 
in carcinoma group, but there were significant differences (P=0.021) in BRAFV600E expression between tumor 
types, that is, all mucinous cases showed positive expression of BRAFV600E (Table 8). 
 
Table (8) Association between the Expression of BRAFV600E with Stage & Grade.  
Carcinoma group No. of cases 
n          % 
Positive 
n          % 
Negative 
n          % 
Fisher 
exact test 
*P 
value 
Histological 
type 
Adenocarcinoma 81          90 3          3.3 78          86.7 1.2 0.021 * 
Mucinous ca. 9           10 9             10 0            0 
Histological 
grade 
Well diff. 29          32.3 1             1.1 28          31.1 4.1 0.915 
Moderately diff. 25          27.7 1            1.1 24          26.7 
Poorly diff. 36          40 10          11.1 26          28.9 
Dukes stage A 15         16.6 0 0 15         16.6 2.6 0.942 
B 1 15          16.6 1            1.1 14          15.6 
B 2 19          21.1 1            1.1 18            20 
C 1 21          23.4 4            4.4 17          18.9 
C 2 20          22.3 6            6.7 14          15.6 
(*P˂ 0.05) 
 3.5 Association of wild BRAF & mutant BRAFV600Ewith clinico pathological features: 
Differences in clinical characteristics between wild BRAF and mutant BRAFV600E tumors are displayed in (Table 
9). Results showed significant differences in age between wild and mutant BRAF, since the positive expression 
of mutant BRAFV600E was 100% in cases >55 years old, in comparison to 51.3%, for wild BRAF (P=0.001). On 
the subject of the gender, BRAFV600E was significantly more likely to occur in females in comparison with wild 
BRAF (58.3% v 44.9%, P=0.0001). As well, the association between BRAFV600E and right-sided tumors was 
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statistically significant, overall, 66.7% of BRAF mutant tumors were right-sided compared to 29.5% for wild-
type tumors (p=0.0001).  
 Although the stage C2 showed larger proportion of BRAFV600E expression compared to wild BRAF (50%v 
25.6%), no statistically significant differences were found between wild and mutant BRAF concerning tumor 
stage (P=0.155), whereas tumor grade displayed high significant differences(p=0.0001) between wild and mutant 
BRAF as the poorly differentiated grade showed highest proportion in BRAFV600E against wild BRAF(83.3% v 
37.2%).  
Finally, highly significant differences(P=0.0001) were detected between wild, mutant BRAF and tumor type, 
since BRAFV600E expression was detected in 75% of mucinous CRC cases in comparison with wild BRAF which 
was highly associated with adenocarcinoma cases,(92.3%) of them showed positive expression of wild BRAF. 
Table (9) Differences between Clinicopathological Features in Wild BRAF & BRAFV600E 
 P value   BRAFV600E 
                   
%         n         
  
 
Wild 
BRAF                       
     
                %
 n              
Clinicopathological 
features 
 
 
*P= 0.001 
 
 100         12
 
 51.3             40 
   
>55 
 
 
Age 
 
 0          0
 
 48.7      38    
≤55 
 
 
**P=0.0001 
 41.7         5 55.1     43   Male 
 
Gender 
 58.3         7 44.9     35  Female 
**P=0.0001 
 
66.7 8     29.5     23 Rt. colon Site 
 
33.3 4  5            70.5           
5 
Lt. colon 
 
 
P=0.155 
 0         0           17.9   14 A Stage 
 8.3         1           17.9   14 B1 
8.3             1           20.5   16 B2 
   33.3         4           17.9   14 C1 
 50         6           25.6   20 C2 
 
**P  =0.0001 
 8.3       133.3          26 Well diff. Grade 
 
 8.3      129.5 23 Mod. diff. 
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 83.3        1037.2 29 Poorly 
diff. 
 
**P =0.0001 
75 9 7.7  6 Mucinous 
ca. 
Tumor 
type 
25 3 92.3 72 Adeno  ca. 
                       (*P≤ 0.001) ( **P≤ 0.0001) 
  BRAF mutations have become an important research topic in cancer biology since the original observation by 
Davies et al. in 2002, who revealed that high frequency of BRAF mutation is a common phenomenon in multiple 
types of cancers[18].  In the current study, the positive expression of wild BRAF was detected in 86.7% of 
malignant cells, 70% of colonic adenoma, and 25% of colitis cases and in 40% of cases with no significant 
pathology, whereas positive expression of mutant BRAFV600E was observed only in 13.3% of CRC cases versus 
totally negative expression in other groups of the study.  
  Our results regarding the immunodetection of wild and mutant BRAF expression in CRC group are close to 
what was reported by Kalady et al. in 2012 who mentioned that only 12% of the samples harbored BRAF 
mutation versus (88%) that harbored wild BRAF [19], and Ben et al. (2014) who reported that (11%) patients 
had BRAF mutant tumors and (89%) had BRAF wild-type tumors [20]. In contrast,  Nicolas et al. in 2015  found 
in their study on CRC patients that mutant BRAF expression was present in (66%) of patients, while it was 
absent in the remaining (34%) of non-mutated patients who have wild type BRAF[17], while Roth  et al. in 2010  
detected 7.9% of BRAF mutation in their study on patients with stage II to III colon cancer[21], and Naguib et 
al. in 2010 conducted that BRAFV600E mutation was found in 15.6% of CRC in their study population[22] as well 
as Phipps et al. in 2012 who reported that BRAFV600E mutation was observed in (12% ) of their study 
population[23].  Chen et al. in 2014 found (10.8%) of BRAFV600Ein CRC patients, and mentioned in their study 
of estimation the effect of BRAFV600E mutation on the clinicopathological characteristics of CRC, that the 
highest BRAFV600E mutation rate was (21.8%) in a study in the United States reported by Shaukat et al.(2010), 
whereas the lowest mutation rate was( 5.0% ) in a study completed in Israel by Rozek et al. (2010). They 
concluded that the differences in BRAF expressions may be attributed to the different ethnicities of the study 
populations [24, 25, 26]. 
    Numerous studies investigated the role of BRAF mutation in cancer development and progression.  In a point 
of view, BRAFV600E mutation, as the most prevalent BRAF mutation, changes the inactive conformation of BRAF 
kinase to a very active state [27]. This simple point mutation leads to a constitutive activation of whole MAPK 
pathway, which mediates the cell surface growth signals to transcriptional activity of cell cycle regulatory genes 
[28]. BRAF V600E mutation, which is virtually absent in hereditary colorectal cancer, is often present in sporadic 
CRC that has a CpG island hypermethylation phenotype (CIMP-high), resulting in hypermethylation of promoter 
regions. BRAF mutated CIMP-high CRC is frequently MSI-H, as the MLH1 promoter has been methylated, 
resulting in an MLH1-deficient tumor [29].  
    Several  publications have reported the possibility of immunodetection of wild and mutated proteins of BRAF 
using a specific monoclonal antibody directed against those proteins;  Yu et al. in 2009 generated monoclonal 
antibodies specific to the more frequently mutated BRAF V600E mutation which only reacts with the protein 
product of the BRAFV600E and not with protein associated with other mutations of BRAF[30], as well as Capper 
et al. (2011) who developed a novel mouse monoclonal mutation-specific anti-BRAFV600E antibody, which is 
suitable for immunohistochemistry on routinely processed formalin fixed paraffin embedded tissue that can 
differentiate BRAFV600E and wild type protein[14]. They recommended that using monoclonal antibody may 
substantially facilitate molecular analysis of BRAFV600E status for diagnostic, prognostic, and predictive 
purposes. Koperek and Kornauth in 2012 concluded that IHC for BRAFV600E is more sensitive and specific than 
Sanger sequencing in the routine diagnostic setting and may represent the new gold standard for detection of 
BRAFV600E mutation in papillary thyroid carcinoma [31]. Nicolas et al. in 2015 confirmed the use of 
immunohistochemistry in detecting BRAFV600E mutation protein as an alternative to molecular testing in CRC, 
they reported that immunohistochemical evaluation could also be useful in cases where the quality of the 
material is not suitable for molecular investigation as it is possible to assess diagnosis of malignant tumors only 
by the presence of scattered cells in the specimen compared with molecular techniques which require at least 5% 
of tumoral cells in the tested sample[17].    
The current result about the expression of wild and mutant BRAF expression in tumor free tissues (no significant 
pathology cases), match with Capper et al.  in 2011 who reported that normal tissue surrounding the tumor was 
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BRAFV600E negative, and the investigation of the wild type cases using antibody of wild BRAF revealed equally 
large amounts of total BRAF protein as in BRAFV600E mutated cases[14]. 
Conversely, the present results concerning the expression of wild and mutant BRAF  in cases of colonic 
adenoma, agree with Rosenberg et al. in 2007who reported that BRAFV600E mutation was identified in (10\16)of 
serrated adenomas compared with(1\33) of conventional adenoma(P= 0.001)[32], and with Spring et al. in 2006 
who concluded in their study on patients with adenomas (tubular &  tubulovillous adenomas), that BRAF 
mutation was rare in adenomas since they detected the mutation in 1/248 (0.4%)of cases [33], as well, Carr et al. 
in 2009 mentioned that BRAF mutation was detected in 2/42 (5%) of conventional  adenomas [34]. Kambara  et 
al. in 2004found that none of (28) of conventional adenomas cases had BRAF mutation compared to other types 
(sessile serrated adenoma (75%), mixed polyps (89%), hyperplastic polyps (19%), serrated adenomas (20%), and 
conventional adenomas (0%) (p<0.001) [35]. Sclafani et al. in 2013 reported in their meta-analysis study that 
approximately ( 6–85% )of hyperplastic polyps,( 20–100%) of mixed polyps, and( 20–100% ) of serrated 
adenomas have been reported to harbor a BRAF mutations compared to only( 0–5% )of conventional 
adenoma[36]. Nevertheless, it was suggested by some studies that BRAFV600E mutation was detected in much 
more frequency in adenomas, of them; Beach et al. in 2005  detected BRAF mutation in 30% of tubular 
adenomas[37]. Lee et al. in 2005mentioned that mutant BRAF expression was found in 27 (77.1%) of serrated 
adenomas and (7\13) of hyperplastic polyps, recommending that BRAF mutations are early and a critical event 
in serrated adenomas, and most serrated adenomas in both sides of colon may progress from micro-vesicular 
hyperplastic polyps via BRAF mutations[38]. On the other hand, Chan et al. in 2003  reported that BRAF 
mutations were detected in 18 /50 (36%) hyperplastic polyps, 2/10 (20%) admixed hyperplastic polyp/adenomas, 
and 9 / 9 (100%) serrated adenomas. they concluded that acquisition of a BRAF mutation appears to be 
associated with the progression of hyperplastic polyp to serrated adenoma, and suggested that the high incidence 
of BRAF mutations in hyperplastic polyps and serrated adenomas is consistent with the concept that the group of 
CRC carrying BRAF mutations may harbor most that have progressed through the hyperplastic polyp - serrated 
adenoma-carcinoma pathway[39].  In accordance with the theory of BRAF mutation as an early event in 
colorectal tumourigenesis, a recent systematic review of published data demonstrated a high concordance rate 
(98%) of BRAF mutations between primary and metastatic tumors [40].     
In the present study, wild BRAF did not associated with age, gender, tumor type, grade and location. 
Surprisingly, all BRAFV600Eexpression was detected in patients above 55, with significant differences (P=0.047), 
and this is compatible with Roth et al. in 2010 who confirmed that BRAF mutation was highly significant 
associated with older age[21] and with Chen et al. in 2014 who demonstrated  in their analysis that (18.6%) of 
patients were 60 years or older, were BRAFV600E mutation positive, compared with (6.7%) of patients younger 
than 60 years old, detecting a significant association between BRAFV600E mutation and age 60 years or older[24]. 
As well, Tie et al. in 2011 reported that the prevalence of BRAFV600E was considerably higher(P=0.04) in 
older(age > 70)[41], as well as, Lubomierski et al. in 2005 reported that the median age of patients with 
BRAFV600E was older compared with the median age of patients without this mutation (P = 0.001; 78 vs. 49 
years)[42].  Berg et al. in 2010 recorded in their work that BRAF mutation in patients ˂50 was 7% while in 
those >70 was 19%, recommending that BRAF mutation increased with patient's age[43]. However, the 
association of BRAF mutations with age and gender is controversial and has not been demonstrated in other 
studies [36, 44]. 
The current Results showed that BRAFV600Eexpression was significantly related (p=0.041) to right sided colon, 
this is in agreement with Fariña-Sarasqueta et al. in 2010 who mentioned that BRAFV600E mutation was 
significantly associated with right-side location (P< 0.001)[44], and with Roth et al. in 2010 who reported that  
BRAF mutations were highly significantly more frequent in right-sided colon tumors(P < 10- 4)[21]. As well, 
Zlobec et al. in 2010 concluded that BRAF gene mutation is an adverse prognostic factor in right-sided colon 
cancer patients independent of MSI status and, moreover, the molecular analysis for BRAF may be a useful 
biomarker for identifying patients with right-sided colon cancer with poor outcome who may benefit from a 
more individualized course of therapy[35].  Tie et al. in 2011 recorded that right-sided tumor location (p< 
0.0001) were independently associated with BRAFV600E [41]. And Chen et al. in 2014 observed that (21.6%) of 
patients with tumors in the proximal colon were BRAFV600E mutation positive, compared with (4.8%) of patients 
with distal colon or rectal tumors, they detected a significant association between BRAFV600E mutation and 
proximal colon tumor location[24]. Also, Sclafani et al. in 2013concluded that BRAF mutations have been found 
to occur significantly more frequently in tumors arising from the right colon than left colon with a percentage of 
(57–89%  vs  11–43%)[36].  In contrast, Yuen et al. in 2002 found (45) tumors in the right colon and (170) in the 
left colon [46]. The explanation of being BRAF mutation tumors more prevalent in right side than left side may 
be return to a higher frequency of MSI which is a poor prognostic factor in CRC, has been reported to be more 
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prevalent in right side compared to left side of colon[47, 48]. Other hand, Benedix et al. in 2012 suggested that 
these differences between right and left sided colon are more related to the anatomical site of the cancer origin 
rather than simple right and left categorization [49]. Otherwise, despite a number of descriptive studies on the 
prevalence of BRAF mutation and its correlation with clinicopathological characteristics, there has been no 
comprehensive comparison on the effect of BRAF mutation on patient's survival in separate groups of right and 
left colon cancers [28]. 
    Also in this work, a significant association was detected between BRAFV600E expression and tumor type 
(P=0.021), since all mucinous cases which account for (10%) of total CRC cases in this study, showed positive 
expression of this marker. This finding agreed with what was reported by Yoshitake et al. in 2007, who recorded 
in their study of evaluation the status of BRAF and other markers to clarify their association with tumorigenesis 
of colorectal mucinous carcinoma, that all mucinous colorectal carcinoma cases harbor BRAF mutation, 
recommending that BRAF mutation plays an important role in the tumorigenesis of colorectal mucinous 
carcinoma [50]. Chen et al. in 2014 detected a rate (19.4%) of patients with mucinous histology were 
BRAFV600E mutation positive, whereas (8.1%) of patients with non-mucinous histology were 
BRAFV600E mutation positive, observing a significant association between BRAFV600E mutation and mucinous 
histology [24].  Other work by Tanaka et al. in 2006 observed BRAF mutation in (46% ) of mucinous CRC 
versus (16%) of non- mucinous CRC ( p < 0.01) [51].  Li WQ et al. in 2006 explained in their work that 
BRAFV600E mutation is 5-10folds more frequent in tumors with high grade and mucinous appearance (P< 0.002 
for each)[52], and Fariña-Sarasqueta et al. in 2010  agreed that the BRAFV600E mutation confers a worse 
prognosis to stage II and stage III colon cancer patients independently of disease stage and therapy[44], other 
study by Ogino et al. in 2012 found that BRAF mutations were more frequent in the mucinous (27%) than non-
mucinous carcinoma (8.6%) (P<0.001)[9].  
  Other finding in this study revealed that wild BRAF is associated with tumor stage since it was expressed 
mainly in cases of stage C, while no significant association was noticed in mutant BRAFV600E expression among 
tumor stages, and this is in accordance with Roth et al. in 2010 who explained that BRAFV600E expression were 
not significantly different according to tumor stage[21], compared with Tie et al. in 2011 who suggested that 
BRAF expression is associated with poorer outcomes in CRC patients[41]. Other works by Gavin et al. in 2012, 
de Roock et al.  in 2010 and Oikonomou et al. in 2014, who referred in their adjuvant studies in patients with 
stage II/III colon cancer and in metastatic disease, that BRAFV600E mutation is associated with worse clinical 
outcome, and agreed that immunodetection of BRAFV600E mutation could provide prognostic information[53, 54, 
55]. Yuan et al. in 2013 stated in their study that BRAF mutation is a predictive biomarker of poor prognosis in 
metastatic CRC patients treated by anti-EGFR monoclonal antibodies, especially in KRAS wild-type patients 
[56]. However, Phipps et al. in 2012 concluded that the prevalence of BRAF mutations in CRC differs by patient 
and tumor characteristics and suggest that the association between BRAF status and CRC survival may differ by 
some of these factors [23].   
 With the exception of tumor stage which displayed insignificant differences, the results of this study revealed 
significant differences in the clinicopathological features concerning age, gender, tumor site, grade and type 
between wild and mutant BRAF, which indicate that mutant BRAF is associated with bad prognosis in CRC 
patients since it is significantly correlated with high grade and mucinous type of cancer. And this is match with 
Clancy et al.  in 2013 who concluded that BRAF mutation appears to be associated with distinct, unfavorable 
clinicopathological characteristics in CRC[57], and with Chen  et al. in 2014who demonstrated that the 
BRAFV600E mutation in CRC was associated with advanced TNM stage, poor differentiation, mucinous 
histology, female gender, older age, proximal colon, concluding that BRAFV600E mutation was significantly 
correlated with adverse pathological features of CRC and distinct clinical characteristics. They suggested that 
BRAFV600Emutation could be used to supplement standard clinical and pathological staging for the better 
management of individual CRC patients, and could be considered as a poor prognostic marker for CRC as well 
as could alert physicians to patients that may be at increased risk of carrying a BRAFV600E mutant tumor as the 
focus for screening [24]. As well, Ardekani et al. in 2012 found that BRAF mutation increases the risk of 
mortality in CRC patients for more than two folds, and concluded that BRAF mutation is an absolute risk factor 
for patient's survival in CRC since the risk of mortality in CRC patients harboring BRAF mutation is more than 
2 folds higher than those with wild BRAF. They recommended that the key regulatory role of BRAF mutation in 
MAPK pathway is to block signaling pathway for cancer treatment[28].  However, the response rate of CRC 
patients harboring BRAF mutation to BRAF inhibitor treatments is much lower than other types of cancers [21]. 
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In the present study, BRAFV600E mutation was significantly associated with several clinical and pathological 
factors. Therefore, we infer that BRAFV600E mutations may play an important role in tumor development and the 
subsequent prognosis. 
 
4. Conclusions: 
There were significant differences in the expression of BRAF in patients with Dukes' stage A, B and C colorectal 
cancer. BRAFV600E mutation was positive only in carcinoma group and associated significantly with different 
clinical and pathological factors. Therefore, we infer that BRAFV600E mutations may be a promising tool for early 
detection of micrometastatic circulating tumor cells in CRC patients. And there were significant differences 
between wild BRAF and mutant BRAFV600E in relation to patients' age, female sex, right-sided colon tumor, 
tumor type and grade. Those results suggest that both markers are useful tool for determining which patients are 
at high risk for recurrence and poor prognosis. 
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